Kainos Medicine Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
25
- Investments
-
2
- Share Price
-
$16.44
- (As of Thursday Closing)
Kainos Medicine General Information
Description
Developer of novel drugs intended to provide research and develop various medicines for cancers and brain and infectious diseases in South Korea and internationally. The company's product pipeline includes KM-819, which is under phase I clinical study for the treatment of Parkinson's disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is under phase II clinical study to treat HIV/AIDS, thereby providing healthcare companies and healthcare professionals with the various treatment for novel diseases such as brain diseases and cancers.
Contact Information
Website
www.kainosmedicine.comCorporate Office
- 3F, Building. A, Korea Bio-Park, 700 Daewangpangyo-ro
- Bundang-gu, Gyeonggi-do
- Seongnam-si, 13488
- South Korea
Corporate Office
- 3F, Building. A, Korea Bio-Park, 700 Daewangpangyo-ro
- Bundang-gu, Gyeonggi-do
- Seongnam-si, 13488
- South Korea
Kainos Medicine Timeline
Kainos Medicine Stock Performance
(As of Thursday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$16.44 | $16.29 | $9.10 - $19.02 | $231M | 14.1M | 36K | -$0.49 |
Kainos Medicine Financials Summary
In Thousands, USD |
TTM 31-Dec-2019 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 | FY 2017 31-Dec-2017 |
---|---|---|---|---|
EV | 189,988 | 189,988 | 161,753 | 80,738 |
Revenue | 1,921 | |||
EBITDA | (6,494) | (6,494) | (7,061) | (2,091) |
Net Income | (6,805) | (6,805) | (7,228) | (2,314) |
Total Assets | 4,747 | 4,747 | 7,323 | 7,100 |
Total Debt | 179 | 179 | 0 | 66 |
Kainos Medicine Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Kainos Medicine Patents
Kainos Medicine Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-4444716-A1 | Compositions and methods for treating cancer | Pending | 06-Dec-2021 | ||
CA-3215574-A1 | Fas-associated factor 1 (faf1)-loaded exosomes and use thereof as anti-cancer agent | Pending | 30-Mar-2021 | ||
AU-2022247243-A1 | Fas-associated factor 1 (faf1)-loaded exosomes and use thereof as anti-cancer agent | Pending | 30-Mar-2021 | ||
JP-2024512691-A | Fas-associated factor 1 (faf1)-containing exosomes and their use as anticancer agents | Pending | 30-Mar-2021 | ||
EP-4316467-A1 | Fas-associated factor 1 (faf1)-loaded exosomes and use thereof as anti-cancer agent | Pending | 30-Mar-2021 | A61K38/1761 |
Kainos Medicine Signals
Kainos Medicine Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Kainos Medicine Investments & Acquisitions (2)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
FAScinate Therapeutics | 01-Aug-2020 | Drug Discovery | |||
Hana Financial Eleventh Special Purpose Acquisition | 08-Jun-2020 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) |
Kainos Medicine FAQs
-
When was Kainos Medicine founded?
Kainos Medicine was founded in 2007.
-
Where is Kainos Medicine headquartered?
Kainos Medicine is headquartered in Seongnam-si, South Korea.
-
What is the size of Kainos Medicine?
Kainos Medicine has 25 total employees.
-
What industry is Kainos Medicine in?
Kainos Medicine’s primary industry is Drug Discovery.
-
Is Kainos Medicine a private or public company?
Kainos Medicine is a Public company.
-
What is the current stock price of Kainos Medicine?
As of 14-May-2020 the stock price of Kainos Medicine is $16.44.
-
What is the current market cap of Kainos Medicine?
The current market capitalization of Kainos Medicine is $231M.
-
What is Kainos Medicine’s annual earnings per share (EPS)?
Kainos Medicine’s EPS for 12 months was -$0.49.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »